Effects of Cell-permeable Ceramides and Tumor Necrosis Factor-alpha on Insulin Signaling and Glucose Uptake in 3T3-L1 Adipocytes
Overview
Authors
Affiliations
Incubation of 3T3-L1 adipocytes with C2- and C6-ceramides (N-acetyl- and N-hexanoylsphingosines) but not dihydro-C2-ceramide increased 2-deoxyglucose uptake in the absence of insulin. This effect was inhibited by PD 98059, LY 294002, and rapamycin, which block the activation of mitogen-activated protein kinase, phosphatidylinositol (PI) 3-kinase, and ribosomal S6 kinase, respectively. Long-term increases in PI 3-kinase activity associated with insulin receptor substrate 1 (IRS-1) increased GLUT1 and GLUT4 concentrations in plasma membranes. This together with increased GLUT1 (but not GLUT4) synthesis explains the increase in non-insulin-dependent glucose uptake. C2-ceramide inhibited insulin-stimulated glucose uptake after 2 h by decreasing insulin-induced translocation of GLUT1 and GLUT4 to plasma membranes. This occurred when there was no increase in basal glucose uptake or decrease in activation of IRS-1 or PI 3-kinase. Incubation for 24 h with tumor necrosis factor-alpha (TNF-alpha) but not C2-ceramide decreased the concentration and insulin-induced tyrosine phosphorylation of IRS-1 in this experimental system. Cell-permeable ceramides mimic some effects of TNF-alpha, especially in stimulating basal glucose uptake. We identified a site for inhibiting insulin-stimulated glucose uptake that is downstream of PI 3-kinase. Our work provides further mechanisms for the effects of TNF-alpha and ceramides in increasing non-insulin-dependent glucose uptake and decreasing insulin-stimulated uptake in vivo.
Seal A, Hughes M, Wei F, Pugazhendhi A, Ngo C, Ruiz J Int J Mol Sci. 2024; 25(5).
PMID: 38474268 PMC: 10932382. DOI: 10.3390/ijms25053024.
Ceramides are fuel gauges on the drive to cardiometabolic disease.
Wilkerson J, Tatum S, Holland W, Summers S Physiol Rev. 2024; 104(3):1061-1119.
PMID: 38300524 PMC: 11381030. DOI: 10.1152/physrev.00008.2023.
Brusatori M, Wood M, Tucker S, Maddipati K, Koya S, Auner G J Diabetes. 2022; 14(4):271-281.
PMID: 35470585 PMC: 9060146. DOI: 10.1111/1753-0407.13262.
You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.
Varre J, Holland W, Summers S Biochim Biophys Acta Mol Cell Biol Lipids. 2022; 1867(6):159125.
PMID: 35218934 PMC: 9050903. DOI: 10.1016/j.bbalip.2022.159125.
Ceramides in Metabolism: Key Lipotoxic Players.
Chaurasia B, Summers S Annu Rev Physiol. 2020; 83:303-330.
PMID: 33158378 PMC: 7905841. DOI: 10.1146/annurev-physiol-031620-093815.